Navigation Links
YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
Date:11/11/2009

a shareholders to vote on this transaction is scheduled to occur in January 2010.

    Nimotuzumab

    Nimotuzumab is currently being evaluated in 32 Phase II and III clinical
trials, 11 of which are being conducted by YM's majority owned subsidiary,
CIMYM BioSciences Inc., or its licensees.

    -   Daiichi Sankyo Co., Ltd., CIMYM's licensee for nimotuzumab in Japan,
        and YM's licensee in Korea, Kuhnil Pharmaceutical Co., are currently
        collaborating on a randomized, open-label Phase II trial evaluating
        nimotuzumab plus irinotecan compared to irinotecan alone in patients
        with advanced or recurrent gastric cancer refractory to 5-FU-
        containing regimens which is reportedly expected to complete
        recruitment in calendar 2009. Daiichi Sankyo is also conducting a
        Phase II trial in first-line NSCLC for which completion of
        recruitment is reportedly expected in the first half of 2010.

    -   YM initiated randomized, double-blind Phase II, trials in patients
        with brain metastases from non-small cell lung cancer (NSCLC) and in
        NSCLC patients ineligible for radical chemotherapy. Recruitment
        commenced in Canada in March 2009 for palliative NSCLC and in
        September for the brain metastases trial. A Phase II, second-line,
        single-arm trial in children with progressive diffuse intrinsic
        pontine glioma (DIPG) is ongoing at multiple sites in the US, Canada,
        and Israel.

    -   Oncoscience AG (OSAG), CIMYM's licensee for Europe, reported
        completion of recruitment in a single-arm, Phase III trial of
        nimotuzumab as first-line therapy for DIPG in August 2007, and the
        preliminary data from this trial that was released at ASCO in 2008
        was expanded on at the annual international pediatric oncology forum,
        SIOP, held in Sao Paulo, Brazil in October 2009. OSAG advises that,
        based on the data it plans to submit a Pediatr
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  Technology Applications International Corporation (the "Company" ... subsidiary Renuell Int,l, Inc. has signed an additional exclusive ... ("NASA") at the Johnson Space Center in ... tapplic.com/houstonphotos/ Charles J. ... to announce our latest, exclusive agreement with NASA. In ...
(Date:9/2/2014)... - Oncothyreon Inc. (Nasdaq: ONTY ) announced today that ... will present at the Rodman & Renshaw 16 th ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... presentation will be accessible by visiting the Oncothyreon website ... About Oncothyreon Oncothyreon is a biotechnology ...
(Date:9/2/2014)... Culot brings life science and ... services  BioData, producer of Labguru, the web-based ... the appointment of Louis Culot as the ... Marketing and Business Development at BioDiscovery Inc., developer of ... Previously, Culot worked for 17 years with ...
(Date:8/31/2014)... 2014 Wockhardt Limited today announces a major ... research when two of its drugs, WCK 771 and ... (QIDP) status from U.S. Food & Drug Administration (FDA). ... pathogens which have a high degree of unmet need ... Disease Control (a top U.S. government health and safety ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Louis Culot Appointed as BioData's CEO 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3
... ... Delay, LEXINGTON, Mass., ... Glenn L. Cooper,MD, its chairman and chief executive officer is postponing his,previously-announced ... of the recent delay in the approval of NEBIDO(R)., Dr. Cooper ...
... Raymond J. De,Hont, Chairman and Chief Executive Officer ... Fybroc business unit has received,an order for approximately $500,000 ... second and third quarters of the Company,s current fiscal ... order Fybroc has received this year from the,Eastern European ...
... Cell Therapeutics, Inc.,(Nasdaq and MTA: CTIC) today announced that ... million, newly issued 15% Convertible,Senior Notes due 2011, with ... warrant to purchase approximately 14.6 million shares of common ... This transaction constitutes a partial exercise of a previously ...
Cached Biology Technology:Indevus Announces Management Changes 2Indevus Announces Management Changes 3Indevus Announces Management Changes 4Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 2Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 3Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 2
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
(Date:9/2/2014)... study published in the September issue of ... a novel strategy to diagnose the leading cause ... structural damage has occurred. This advance involves quantifying ... the endothelium of retinal vessels. Using new probes ... the early molecular development of diabetic retinopathy. , ...
(Date:9/2/2014)... Best-selling author Sam Kean stops by Reactions this ... 50-foot super shark that, despite what "Shark Week" may ... about it at http://youtu.be/KhFygIoW_MA . , Kean,s book, ... Love and the History of the World from the ... treatment in a 10-episode video series produced for the ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... optogenetics, the researchers are able to target one cell ... to find out exactly what goes wrong in the ... Prof. Dr. Stefan Herlitze (RUB Department for Biology and ... Biological Chemistry . The Bochum team examined a specific ...
... MD FASEB MARC (Minority Access to Research Careers) ... 2011 Society for Leukocyte Biology (SLB) Meeting in Kansas ... are meant to promote the entry of underrepresented minority ... basic science community and to encourage the participation of ...
... - Researchers speaking on the final day of the 6th ... 2011) have focused on the growing interest in the scientific ... have been growing over the past 12 months and are ... Society (IAS) convened working group concentrating its initial efforts on ...
Cached Biology News:Controlling movements with light 2 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 2 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 3 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 4
QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Biology Products: